Theriva Financial Statements From 2010 to 2025

TOVX Stock  USD 1.47  0.15  9.26%   
Theriva Biologics financial statements provide useful quarterly and yearly information to potential Theriva Biologics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Theriva Biologics financial statements helps investors assess Theriva Biologics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Theriva Biologics' valuation are summarized below:
Market Capitalization
4.5 M
Earnings Share
(32.59)
We have found one hundred twenty available fundamental trend indicators for Theriva Biologics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Theriva Biologics current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 6 M in 2025. Enterprise Value is likely to rise to about (28.3 M) in 2025
Check Theriva Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theriva Biologics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 101.5 K, Total Revenue of 0.0 or Other Operating Expenses of 13.9 M, as well as many indicators such as Price To Sales Ratio of 241, Dividend Yield of 0.0 or PTB Ratio of 0.19. Theriva financial statements analysis is a perfect complement when working with Theriva Biologics Valuation or Volatility modules.
  
Check out the analysis of Theriva Biologics Correlation against competitors.
For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.

Theriva Biologics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets66.7 M63.5 M32.1 M
Slightly volatile
Total Current Liabilities4.2 M7.7 M6.1 M
Pretty Stable
Accounts Payable1.1 M885.5 K1.2 M
Very volatile
Cash28 M26.7 M21.5 M
Slightly volatile
Non Current Assets Total33.6 M32 M7.9 M
Slightly volatile
Cash And Short Term Investments28 M26.7 M21.5 M
Slightly volatile
Liabilities And Stockholders Equity66.7 M63.5 M32.1 M
Slightly volatile
Other Stockholder Equity418.1 M398.2 M214.4 M
Slightly volatile
Total Liabilities18.7 M17.9 M9.8 M
Slightly volatile
Total Current Assets33.1 M31.5 M24.2 M
Slightly volatile
Other Current Liabilities6.5 M6.2 M5.1 M
Pretty Stable
Property Plant And Equipment Net2.6 M2.5 M951 K
Slightly volatile
Short and Long Term Debt Total1.9 M1.9 MM
Slightly volatile
Short Term Debt529.4 K495 K307.2 K
Slightly volatile
Net Receivables2.3 M2.2 M557.9 K
Slightly volatile
Non Current Liabilities Total10.6 M10.1 M3.6 M
Slightly volatile
Short Term Investments338.7 K294.7 K338.1 K
Slightly volatile
Intangible Assets23.9 M22.7 M18.5 M
Slightly volatile
Common Stock15.4 K16.2 K67.1 K
Slightly volatile
Common Stock Shares Outstanding1.1 M740.9 K1.3 M
Slightly volatile
Other Liabilities10.7 M10.2 M4.2 M
Slightly volatile
Capital Stock2.4 M2.5 M12.9 M
Slightly volatile
Net Working Capital30.6 M23.8 M26.9 M
Pretty Stable
Property Plant Equipment1.1 M1.8 M882.6 K
Slightly volatile
Capital Lease Obligations1.3 M2.2 MM
Slightly volatile
Property Plant And Equipment Gross2.3 M3.7 MM
Slightly volatile
Long Term Debt153.2 K145.8 K208.4 K
Slightly volatile
Deferred Long Term Liabilities15.3 M17.2 M18.8 M
Slightly volatile
Short and Long Term Debt66 K72.5 K58.9 K
Slightly volatile
Non Current Liabilities Other5.4 M5.6 M6.9 M
Slightly volatile
Current Deferred Revenue2.3 M2.6 M2.8 M
Slightly volatile

Theriva Biologics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses13.9 M24.6 M19.1 M
Pretty Stable
Cost Of Revenue183.7 K155.2 K205.6 K
Pretty Stable
Total Operating Expenses13.9 M24.6 M19.1 M
Pretty Stable
Research Development9.5 M16.5 M13.1 M
Very volatile
Interest Expense519.2 K494.5 K181.9 K
Slightly volatile
Net Interest Income1.7 M1.7 M393.1 K
Slightly volatile
Interest Income1.7 M1.7 M393.1 K
Slightly volatile
Selling General Administrative7.1 M8.2 M6.2 M
Slightly volatile
Reconciled Depreciation134.1 K108.9 K214.1 K
Slightly volatile
Selling And Marketing Expenses499.2 K561.6 K612.3 K
Slightly volatile

Theriva Biologics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow50.6 M48.2 M22.9 M
Slightly volatile
End Period Cash Flow28.1 M26.8 M21.6 M
Slightly volatile
Stock Based Compensation472 K496.8 K1.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio241254391
Slightly volatile
Days Sales Outstanding82.9887.35117
Slightly volatile
Average Payables761.9 K383.2 K405.1 K
Pretty Stable
Stock Based Compensation To Revenue0.230.240.3954
Slightly volatile
EV To Sales188198203
Slightly volatile
Payables Turnover0.310.20.1575
Slightly volatile
Average Inventory0.40.450.4906
Slightly volatile
Research And Ddevelopement To Revenue0.430.451.1356
Slightly volatile
Capex To Revenue0.00340.00360.0162
Slightly volatile
Cash Per Share39.3241.39106
Slightly volatile
Days Payables Outstanding4.5 K2.4 K8.9 K
Slightly volatile
Income Quality0.680.930.8952
Slightly volatile
Intangibles To Total Assets0.440.410.342
Slightly volatile
Net Debt To EBITDA0.660.951.129
Slightly volatile
Current Ratio5.243.668.3175
Slightly volatile
Receivables Turnover2.314.324.3504
Pretty Stable
Graham Number217229456
Slightly volatile
Debt To Equity0.00680.00650.0149
Slightly volatile
Capex Per Share0.340.360.7374
Slightly volatile
Average Receivables28.3 K38.7 K40.9 K
Very volatile
Revenue Per Share46.7444.5145.9959
Slightly volatile
Interest Debt Per Share0.380.41.7937
Slightly volatile
Debt To Assets0.00350.00370.0115
Slightly volatile
Days Of Payables Outstanding4.5 K2.4 K8.9 K
Slightly volatile
Ebt Per Ebit0.680.840.9276
Slightly volatile
Total Debt To Capitalization0.00680.00650.0142
Slightly volatile
Debt Equity Ratio0.00680.00650.0149
Slightly volatile
Quick Ratio5.433.668.328
Slightly volatile
Net Income Per E B T1.341.061.018
Pretty Stable
Cash Ratio4.733.17.4663
Slightly volatile
Days Of Sales Outstanding82.9887.35117
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.161.0231
Slightly volatile
Fixed Asset Turnover5.855.575.9002
Slightly volatile
Debt Ratio0.00350.00370.0115
Slightly volatile
Price Sales Ratio241254391
Slightly volatile
Asset Turnover0.730.690.7177
Slightly volatile
Gross Profit Margin0.630.770.8299
Slightly volatile

Theriva Biologics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market CapM6.3 MB
Slightly volatile

Theriva Fundamental Market Drivers

Cash And Short Term Investments23.2 M

Theriva Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Theriva Biologics Financial Statements

Theriva Biologics investors use historical fundamental indicators, such as Theriva Biologics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Theriva Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.6 M2.3 M
Cost Of Revenue155.2 K183.7 K
Stock Based Compensation To Revenue 0.24  0.23 
Research And Ddevelopement To Revenue 0.45  0.43 
Revenue Per Share 44.51  46.74 
Ebit Per Revenue(0.58)(0.60)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Theriva Stock Analysis

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.